Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Risperidone

FDA-approved product (tablet, oral), marketed as Perseris Kit, Risperdal, Risperdal Consta and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Risperidone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aggressive behavior
  • Autism
  • Bipolar disorder
  • Bipolar I disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA66.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli54.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Risperidone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Risperidone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects

    NCT07490353 · start 2025-11-01

    Registered record
    Registry ID
    NCT07490353
    Conditions
    Depression - Major Depressive Disorder; Anhedonia
    Interventions
    Psilocybin (Usona Institute); Risperidone 1 MG; MRI
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2025-11-01
    Completion
    2028-05-31
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression - Major Depressive Disorder; Anhedonia
    InterventionPsilocybin (Usona Institute); Risperidone 1 MG; MRI
    PhasePhase 1
    Registry statusRecruiting

  • Measurement of Treatment Effects

    NCT07024303 · start 2025-06-15

    Registered record
    Registry ID
    NCT07024303
    Conditions
    Challenging Behavior; Autism Spectrum Disorder
    Interventions
    Psychotropic medication (at discretion of psychiatrist); Behavioral therapy
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2025-06-15
    Completion
    2027-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChallenging Behavior; Autism Spectrum Disorder
    InterventionPsychotropic medication (at discretion of psychiatrist); Behavioral therapy
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Effect of Increasing Total Antioxidant Capacity in Autism Spectrum Disorder

    NCT06623227 · start 2024-09-28

    Registered record
    Registry ID
    NCT06623227
    Conditions
    Autism Spectrum Disorder
    Interventions
    Placebo; Vitamin E and C
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2024-09-28
    Completion
    2025-06-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism Spectrum Disorder
    InterventionPlacebo; Vitamin E and C
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis

    NCT06060886 · start 2023-11-01

    Registered record
    Registry ID
    NCT06060886
    Conditions
    Schizophrenia; Treatment-resistant Schizophrenia; Side Effect; Lipid Metabolism Disorders; Diabetes; NAFLD; Psychosis
    Interventions
    Aripiprazole; Paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-11-01
    Completion
    2025-12-31
    Enrolment
    244

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Treatment-resistant Schizophrenia; Side Effect; Lipid Metabolism Disorders +3 more
    InterventionAripiprazole; Paliperidone
    PhasePhase 4
    Registry statusUnknown

  • Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse

    NCT05480046 · start 2022-10-18

    Registered record
    Registry ID
    NCT05480046
    Conditions
    Schizophrenia
    Interventions
    Risperidone ISM
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-10-18
    Completion
    2025-03-13
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionRisperidone ISM
    PhaseNot recorded
    Registry statusCompleted

  • Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis

    NCT04529226 · start 2020-11-26

    Registered record
    Registry ID
    NCT04529226
    Conditions
    Psychosis; Intellectual Disability
    Interventions
    Clozapine; haloperidol, pimozide, olanzapine, risperidone, amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-11-26
    Completion
    2025-12-30
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychosis; Intellectual Disability
    InterventionClozapine; haloperidol, pimozide, olanzapine, risperidone, amisulpride
    PhasePhase 2
    Registry statusUnknown

  • Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"

    NCT04312503 · start 2020-07-13

    Registered record
    Registry ID
    NCT04312503
    Conditions
    Schizophrenia
    Interventions
    Lurasidone; aripiprazole, olanzapine, quetiapine or risperidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-07-13
    Completion
    2022-10-31
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone; aripiprazole, olanzapine, quetiapine or risperidone
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting

  • A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic

    NCT03568500 · start 2018-05-21

    Registered record
    Registry ID
    NCT03568500
    Conditions
    Schizophrenia; Schizoaffective Disorder; First Episode Psychosis
    Interventions
    Digital Medicine System; Aripiprazole; Olanzapine; Quetiapine; Risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-05-21
    Completion
    2019-09-06
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder; First Episode Psychosis
    InterventionDigital Medicine System; Aripiprazole; Olanzapine; Quetiapine +1 more
    PhasePhase 4
    Registry statusCompleted

  • 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

    NCT01844700 · start 2013-07

    Registered record
    Registry ID
    NCT01844700
    Conditions
    High Risk MC4R Genotype; Low Risk MC4R Genotype; One Week or Less Antipsychotic Lifetime Exposure
    Interventions
    Ziprasidone; aripiprazole, quetiapine, or risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2013-07
    Completion
    2014-04
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Risk MC4R Genotype; Low Risk MC4R Genotype; One Week or Less Antipsychotic Lifetime Exposure
    InterventionZiprasidone; aripiprazole, quetiapine, or risperidone
    PhasePhase 4
    Registry statusTerminated

  • Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

    NCT01774435 · start 2012-10

    Registered record
    Registry ID
    NCT01774435
    Conditions
    Schizophrenia
    Interventions
    EN3342
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-10
    Completion
    2013-10
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionEN3342
    PhasePhase 1
    Registry statusCompleted

  • A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia

    NCT01592110 · start 2012-07

    Registered record
    Registry ID
    NCT01592110
    Conditions
    Schizophrenia
    Interventions
    risperidone-SABER; ZX003:risperidone-SABER and the DosePro System; risperidone-SABER; Risperidone-SABER
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-07
    Completion
    2013-04
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionrisperidone-SABER; ZX003:risperidone-SABER and the DosePro System; risperidone-SABER; Risperidone-SABER
    PhasePhase 1
    Registry statusCompleted

  • The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia

    NCT04076371 · start 2012-01

    Registered record
    Registry ID
    NCT04076371
    Conditions
    Schizophrenia
    Interventions
    olanzapine-sertraline combination; only olanzapine; risperidone-sertraline combination; only risperidone; paliperidone-sertraline combination; only paliperidone; ziprasidone-sertraline combination; only ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-01
    Completion
    2018-12
    Enrolment
    1,640

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionolanzapine-sertraline combination; only olanzapine; risperidone-sertraline combination; only risperidone +4 more
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea

    NCT01423487 · start 2011-08

    Registered record
    Registry ID
    NCT01423487
    Conditions
    Weight Gain; Amenorrhea
    Interventions
    Metformin; Starch tablets
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2011-08
    Completion
    2013-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWeight Gain; Amenorrhea
    InterventionMetformin; Starch tablets
    PhaseNot applicable
    Registry statusWithdrawn

  • PHARMO Institute Seroquel Safety Study

    NCT01342120 · start 2010-09

    Registered record
    Registry ID
    NCT01342120
    Conditions
    Schizophrenia; Major Depressive Disorder; Bipolar Disorder; Generalized Anxiety Disorder
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-09
    Completion
    2010-11
    Enrolment
    18,325

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Major Depressive Disorder; Bipolar Disorder; Generalized Anxiety Disorder
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted